

May 27, 2015



# Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in June 2015

SOUTH SAN FRANCISCO, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will webcast its presentations at the below listed investor conferences in June 2015.

- Isaac Ciechanover, the company's President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference at 4:00 p.m. EDT, Wednesday, June 3, 2015 at the Grand Hyatt New York in New York City, New York.
- Isaac Ciechanover, the company's President and Chief Executive Officer, will present at the Goldman Sachs 36<sup>th</sup> Annual Global Healthcare Conference at 2:40 p.m. PDT, Tuesday, June 9, 2015 at the Terranea Resort in Rancho Palos Verdes, Calif.

The live audio webcasts of the company presentations will be accessible from the company's investor relations website at <http://investors.atarabio.com/events.cfm>. Please connect to the website prior to the start of the presentations to ensure adequate time for any software downloads that may be necessary to listen to the webcasts. An archive of the webcasts will be available for at least 30 days following the presentations.

## About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK), under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including Epstein-Barr virus-targeted cytotoxic T lymphocytes, which recently received breakthrough therapy designation from the Food and Drug Administration, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.

### CONTACT: INVESTOR CONTACT:

Tina Gullotta, Atara Biotherapeutics, Inc.  
650-741-1613  
[tgullotta@atarabio.com](mailto:tgullotta@atarabio.com)

### MEDIA CONTACT:

Susan Heins, Pure Communications, Inc.  
864-286-9597  
[susan@purecommunicationsinc.com](mailto:susan@purecommunicationsinc.com)

Source: Atara Biotherapeutics

